Clin Cancer Res: Low-dose sidna can greatly increase the sensitivity of prostate cancer to dosital!

Dorsey plays an integral role in the treatment of advanced prostate cancer.
, however, more than half of the patients did not respond to dossytherapy, and those who responded well often experienced significant cumulative toxicity, greatly limiting its dose maintenance and strength.
addition of adrenal agents that enhance the initial efficacy of dorsets, maintain the tolerance of the effective dose of dorsets, or improve the prognosis of patients.
Muniyan et al. tested the expression of watergate in the prostate tissue of human and gene-edited mice (GEM) as well as in the cell lineage of tumor sources, and also studied the therapeutic benefits and potential mechanisms of the PDE5 inhibitor sildenafil combined with dositafil.
in human and mouse prostates and cancer cell line, PDE5 was expressed at a higher level than normal tissue/cells.
in the cell line of GEM prostate source, PDE5 increased in order in the cell line of prostate (wild type) epithal cells, androgen dependence, and descesting prostate source.
Compared with dositalt alone, adding a physiologically achievable concentration of sidna fi can enhance the growth inhibition and apoptosis of in vitro prostate cancer cells induced by dositas, and reduce the growth of 3D tumors in mice and tumor-inducing in the body.
addition, Sidnafony can also increase the levels of Dorsey-induced NO and cGMP, thereby enhancing anti-tumor activity.
, the results of this study showed that adding less doses than required to induce cell death increased the sensitivity of prostate cancer cells to dosital chemotherapy.
, for patients with advanced prostate cancer, sildena non-combined dositals may improve anti-tumor activity and reduce chemotherapy-induced adverse reactions.
.